Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:32:47.395Z.
Calculation as of: 2026-10-06T20:32:47.395Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Revelation Biosciences, Inc.
Market Cap
$2.94M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $2.94M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.86M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.66M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
